Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant
Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).